HIV/AIDS

Uptake of New Therapies From Bristol-Myers Squibb/Gilead, Johnson & Johnson/Tibotec, Merck, and Pfizer Will Drive Near-Term Growth in the HIV Drug Market

Published in AIDS Weekly, June 11th, 2007

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continuing uptake of new therapies, including Bristol- Myers Squibb/Gilead's Atripla and Johnson & Johnson/Tibotec's Prezista, and the launch of several novel agents, such as Merck's raltegravir and Pfizer's maraviroc, will drive near-term expansion of the HIV market.

According to the new Pharmacor report Emerging HIV Therapies, Atripla will address the significant need for a more-convenient therapy, while the efficacy of Prezista, raltegravir, and maraviroc will benefit highly treatment- experienced patients. The report, which contains...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2007-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry